Ask Anything
Hot Research Today
Papers from every journal, all in one place. Create custom feeds.
ESC 2026 Hot LineRCT · n=9,97122 mentionsNEJM Highlight
AUG 28ZoungasNew England Journal of Medicine
Atorvastatin cuts major CV events ~30% vs placebo in older adults without improving disability-free survival.
Supports statin initiation for CV prevention in adults ≥70 without CVD; confirms event reduction in primary prevention but leaves disability-free survival benefit open.
ASACC Journal Scan
The risk of heart attack and stroke is a concern for older people and knowing there is an effective measure for lowering that risk will be a huge reassurance to older people and their families. We hope to see updated guidelines to help clinicians make use of these new findings.
ESC 2026 Hot LineRCT · n=51716 mentionsACC Journal Scan (X) Highlight
AUG 28MasriNew England Journal of Medicine
Aficamten improves KCCQ scores by 3 points and peak VO2 vs placebo at 36 weeks.
Provides first targeted option for symptomatic nonobstructive HCM; extends myosin inhibition beyond obstructive disease.
ASACC Journal Scan
For the first time, we have shown clinically meaningful improvements in symptoms and exercise capacity with a treatment that targets the cause of the disease.
ESC 2026 Hot LineRCT · n=3607 mentionsExpert CommentaryACC Journal Scan Highlight
AUG 30HausleiterNew England Journal of Medicine
Transcatheter tricuspid repair cuts death or HF hospitalization ~60% versus medical therapy.
Supports transcatheter tricuspid repair plus medical therapy in symptomatic severe tricuspid regurgitation; delivers first randomized evidence of hard-endpoint benefit.
JHJörg Hausleiter
Among these high-risk patients, transcatheter tricuspid valve repair on top of medical therapy resulted not only in quality-of-life improvements but also in meaningful and sustained reductions in hard clinical outcomes, which has not been demonstrated before with the intervention.
ESC 2026 Hot LineRCT · n=14,19417 mentionsMedscape Cardiology Highlight
AUG 29GibsonNew England Journal of Medicine
Milvexian shows no benefit over placebo for major cardiovascular events after recent ACS.
Milvexian adds no ischemic benefit after ACS; safety supports continued evaluation in ongoing atrial fibrillation and stroke prevention trials.
MCMedscape Cardiology
“Why is this important in terms of safety? Because milvexian is currently being evaluated in two other large trials: one in atrial fibrillation and one in secondary stroke prevention.”
ESC 2026 Hot LineRCT · n=3,1703 mentionsTrending on XACC Journal Scan Highlight
AUG 29LeeNew England Journal of Medicine
Early outpatient CT coronary angiography fails to reduce MI or CV death versus standard care.
Routine early CTCA adds no benefit after MI exclusion; confirms standard care alone suffices for event reduction in this population.
NMNick Mills
BHF Professor of Cardiology, University of Edinburgh, University of Edinburgh
Our findings provide strong evidence that patients who have had a heart attack excluded do not benefit from early outpatient CTCA scans. Once we are confident that they haven't had a heart attack, we can reassure these patients that their future risk is low and send them home.
ESC 2026 Hot LineRCT · n=3,20311 mentionsACC Journal Scan (X) Highlight
AUG 29LeeNew England Journal of Medicine
Clopidogrel monotherapy proves noninferior to extended DAPT for net adverse clinical events in high-risk patients.
May support switching to clopidogrel monotherapy after 12 months to reduce bleeding; extends randomized evidence on DAPT de-escalation in high-ischemic-risk patients.
ASACC Journal Scan
Extended DAPT provided greater protection against major ischemic events, including death, whereas clopidogrel monotherapy reduced major or clinically relevant bleeding. It seems that no single strategy is best for every patient, but rather, long-term antiplatelet therapy should be individualized ...
ESC 2026 Hot LineRCT · n=2,21613 mentionsACC Journal Scan (X) Highlight
AUG 29TakahashiNew England Journal of Medicine
Low-dose prasugrel monotherapy fails non-inferiority to DAPT for death, stroke, or MI.
Prasugrel monotherapy is not noninferior to DAPT after STEMI PCI; challenges early aspirin omission and reinforces dual therapy for ischemic protection.
ASACC Journal Scan
“These findings do not support prasugrel monotherapy at the time of primary PCI for STEMI. It appears that DAPT is needed for at least the first month but the optimum duration of DAPT remains to be determined.”
ESC 2026 Hot LineRCT · n=17,09520 mentionsACC Journal Scan (X) Highlight
AUG 29ÖmerovicNew England Journal of Medicine
Default prasugrel shows no benefit over default ticagrelor for primary events at 1 year.
Neither default policy reduces ischemic events more than the other in ACS after PCI; confirms comparable real-world effectiveness and safety.
ASACC Journal Scan
The implementation gap that exists between carefully controlled randomized trials and routine clinical practice is real and should always be considered by physicians and policymakers.
ESC 2026 Hot LineRCT · n=1,80316 mentionsMedscape Cardiology Highlight
AUG 28KimNew England Journal of Medicine
DOAC therapy cuts major cardiovascular and bleeding events ~69% versus no anticoagulation.
Supports DOAC use in intermediate-risk AF; extends randomized evidence beyond high-risk populations.
BJBoyoung Joung
The key impact on clinical practice is that the level of evidence about this population was actually very low, and this is the first [randomized controlled trial] to support that DOAC therapy can give benefit to this patient population.
ESC 2026 Hot LineRCT · n=9863 mentionsACC Journal Scan Highlight
AUG 30StähliNew England Journal of Medicine
TAVI followed by PCI is noninferior to PCI followed by TAVI for 1-year major events.
PCI timing in TAVR patients with CAD remains unresolved; leaves open whether omitting routine pre-TAVR PCI is safe.
ASACC Journal Scan
Importantly, this was not because coronary access was impaired after TAVI. Rather, once the valve had been treated, the clinical decision about whether PCI was still necessary sometimes changed.